Loading...
Market
Adoption of Enifer's mycoprotein technology by other companies by 2026
4
Resolution / Starting Odds
No adoption • 33%
Adoption by 1-3 companies • 33%
Adoption by 4 or more companies • 34%
Industry news, company announcements
Story
Finnish Startup Enifer Secures €36M for First-of-its-Kind Mycoprotein Factory
May 23, 2024, 07:11 AM
Finnish biotech startup Enifer has secured €36 million in funding to build a first-of-its-kind factory dedicated to producing food-grade mycoprotein in Finland. This innovative project aims to address the global protein shortage by using sidestream materials to create a fungal protein. The factory, now fully funded and ready for construction, will utilize a unique process involving feeding a microbe air and electricity to produce protein without traditional agriculture. The project has garnered support from notable investors including Voima Ventures, FoodTech VC, Taaleri Team, Valio, and ilmastorahasto.
View original story
Similar markets
Voima Ventures • 20%
FoodTech VC • 20%
Taaleri Team • 20%
Valio Ltd • 20%
FinnveraFi • 20%
0-5 countries • 25%
6-10 countries • 25%
11-20 countries • 25%
More than 20 countries • 25%
1-10 countries • 25%
11-20 countries • 25%
21-30 countries • 25%
more than 30 countries • 25%
0-5 countries • 25%
6-10 countries • 25%
11-20 countries • 25%
More than 20 countries • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Another Company • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
16 or more countries • 25%
High adoption by healthcare sector • 25%
High adoption by agricultural sector • 25%
Low adoption by healthcare sector • 25%
Low adoption by agricultural sector • 25%